Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 52 | 2026 | 755 | 10.270 |
Why?
|
| Mental Disorders | 40 | 2026 | 820 | 9.370 |
Why?
|
| Veterans | 50 | 2026 | 760 | 8.860 |
Why?
|
| Criminals | 10 | 2024 | 61 | 3.990 |
Why?
|
| Recidivism | 8 | 2025 | 30 | 3.650 |
Why?
|
| Opioid-Related Disorders | 23 | 2025 | 528 | 3.340 |
Why?
|
| Cocaine-Related Disorders | 19 | 2017 | 81 | 3.130 |
Why?
|
| Mental Health Services | 16 | 2022 | 304 | 2.350 |
Why?
|
| Residential Treatment | 7 | 2025 | 34 | 2.180 |
Why?
|
| Criminal Law | 9 | 2026 | 87 | 1.980 |
Why?
|
| United States Department of Veterans Affairs | 29 | 2026 | 541 | 1.970 |
Why?
|
| Social Stigma | 4 | 2017 | 79 | 1.880 |
Why?
|
| Housing | 9 | 2024 | 74 | 1.820 |
Why?
|
| Adult | 73 | 2026 | 17435 | 1.620 |
Why?
|
| Mental Health | 13 | 2023 | 363 | 1.590 |
Why?
|
| Chronic Pain | 2 | 2026 | 155 | 1.560 |
Why?
|
| Humans | 131 | 2026 | 65385 | 1.540 |
Why?
|
| Schizophrenia | 13 | 2009 | 275 | 1.510 |
Why?
|
| Cocaine | 15 | 2017 | 101 | 1.470 |
Why?
|
| Behavior, Addictive | 6 | 2016 | 75 | 1.440 |
Why?
|
| United States | 43 | 2026 | 8123 | 1.420 |
Why?
|
| Pilot Projects | 16 | 2025 | 1020 | 1.360 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 12 | 2025 | 89 | 1.350 |
Why?
|
| Male | 72 | 2026 | 31147 | 1.290 |
Why?
|
| Antipsychotic Agents | 11 | 2009 | 303 | 1.240 |
Why?
|
| Coercion | 2 | 2022 | 60 | 1.230 |
Why?
|
| Substance Withdrawal Syndrome | 13 | 2005 | 126 | 1.210 |
Why?
|
| Female | 64 | 2026 | 34146 | 1.110 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 85 | 1.080 |
Why?
|
| Middle Aged | 51 | 2026 | 18357 | 1.080 |
Why?
|
| Community Mental Health Services | 3 | 2019 | 95 | 1.070 |
Why?
|
| Behavior Therapy | 3 | 2025 | 169 | 1.010 |
Why?
|
| Analgesics, Opioid | 8 | 2024 | 528 | 1.000 |
Why?
|
| Peer Group | 6 | 2020 | 113 | 0.990 |
Why?
|
| Program Evaluation | 3 | 2019 | 498 | 0.990 |
Why?
|
| Morals | 5 | 2022 | 23 | 0.970 |
Why?
|
| Comorbidity | 12 | 2026 | 1120 | 0.960 |
Why?
|
| Mentoring | 2 | 2022 | 63 | 0.870 |
Why?
|
| Minority Groups | 2 | 2025 | 142 | 0.860 |
Why?
|
| Risperidone | 6 | 2006 | 25 | 0.860 |
Why?
|
| Cues | 9 | 2017 | 81 | 0.790 |
Why?
|
| Opiate Substitution Treatment | 8 | 2024 | 223 | 0.770 |
Why?
|
| Patient Selection | 1 | 2025 | 484 | 0.760 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2023 | 405 | 0.760 |
Why?
|
| Biomedical Research | 1 | 2025 | 262 | 0.740 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 438 | 0.730 |
Why?
|
| Case Management | 3 | 2020 | 53 | 0.710 |
Why?
|
| Benzodiazepines | 4 | 2018 | 107 | 0.670 |
Why?
|
| Drug Overdose | 2 | 2021 | 121 | 0.640 |
Why?
|
| Prisons | 3 | 2019 | 120 | 0.640 |
Why?
|
| Schizophrenic Psychology | 5 | 2009 | 74 | 0.630 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 125 | 0.610 |
Why?
|
| Tobacco Use Disorder | 6 | 2023 | 248 | 0.610 |
Why?
|
| Electroretinography | 9 | 2001 | 26 | 0.600 |
Why?
|
| Social Support | 2 | 2019 | 392 | 0.600 |
Why?
|
| Social Perception | 1 | 2019 | 44 | 0.590 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2019 | 14 | 0.590 |
Why?
|
| Psychiatry | 1 | 2021 | 128 | 0.580 |
Why?
|
| Task Performance and Analysis | 2 | 2018 | 130 | 0.560 |
Why?
|
| Pharmacies | 1 | 2018 | 36 | 0.560 |
Why?
|
| Educational Technology | 1 | 2018 | 9 | 0.550 |
Why?
|
| Treatment Outcome | 13 | 2025 | 5808 | 0.540 |
Why?
|
| Craving | 5 | 2024 | 38 | 0.540 |
Why?
|
| Recovery of Function | 1 | 2019 | 290 | 0.530 |
Why?
|
| Crime | 1 | 2018 | 57 | 0.520 |
Why?
|
| Computer-Assisted Instruction | 1 | 2018 | 80 | 0.520 |
Why?
|
| Attitude to Health | 1 | 2019 | 296 | 0.510 |
Why?
|
| Massachusetts | 8 | 2022 | 2149 | 0.490 |
Why?
|
| Cell Phone | 2 | 2014 | 42 | 0.490 |
Why?
|
| Buprenorphine | 5 | 2023 | 198 | 0.490 |
Why?
|
| Informed Consent | 1 | 2017 | 142 | 0.490 |
Why?
|
| Learning | 1 | 2018 | 186 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 807 | 0.470 |
Why?
|
| Research | 1 | 2016 | 195 | 0.450 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 181 | 0.430 |
Why?
|
| Smoking Cessation | 5 | 2023 | 553 | 0.420 |
Why?
|
| Algorithms | 3 | 2020 | 1049 | 0.400 |
Why?
|
| Cognition Disorders | 3 | 2015 | 224 | 0.400 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 77 | 0.390 |
Why?
|
| Internet | 2 | 2014 | 472 | 0.390 |
Why?
|
| Neuropsychological Tests | 6 | 2003 | 410 | 0.370 |
Why?
|
| Receptors, Opioid, mu | 1 | 2012 | 13 | 0.370 |
Why?
|
| Breathing Exercises | 1 | 2012 | 5 | 0.370 |
Why?
|
| Receptors, GABA-A | 1 | 2012 | 23 | 0.370 |
Why?
|
| Primary Health Care | 2 | 2017 | 724 | 0.350 |
Why?
|
| Counseling | 5 | 2023 | 376 | 0.350 |
Why?
|
| Health Services Needs and Demand | 2 | 2026 | 217 | 0.340 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 151 | 0.340 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2009 | 382 | 0.330 |
Why?
|
| Prisoners | 3 | 2019 | 179 | 0.330 |
Why?
|
| Psychotherapy, Brief | 1 | 2010 | 17 | 0.320 |
Why?
|
| Telemedicine | 2 | 2014 | 372 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 511 | 0.310 |
Why?
|
| Alcoholism | 5 | 2021 | 327 | 0.300 |
Why?
|
| Quality of Life | 4 | 2026 | 1263 | 0.300 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 595 | 0.290 |
Why?
|
| Cluster Analysis | 3 | 2019 | 267 | 0.280 |
Why?
|
| Attitude of Health Personnel | 3 | 2024 | 626 | 0.270 |
Why?
|
| Neural Pathways | 1 | 2008 | 102 | 0.270 |
Why?
|
| Stress, Psychological | 2 | 2024 | 474 | 0.270 |
Why?
|
| Young Adult | 9 | 2024 | 4827 | 0.260 |
Why?
|
| Hospitals, Veterans | 2 | 2018 | 159 | 0.250 |
Why?
|
| Depression | 2 | 2012 | 908 | 0.250 |
Why?
|
| Telephone | 3 | 2023 | 122 | 0.250 |
Why?
|
| Qualitative Research | 6 | 2024 | 755 | 0.250 |
Why?
|
| Veterans Health | 5 | 2021 | 145 | 0.250 |
Why?
|
| Stereotyping | 2 | 2016 | 19 | 0.250 |
Why?
|
| Social Discrimination | 2 | 2016 | 13 | 0.250 |
Why?
|
| Health Status | 4 | 2026 | 446 | 0.250 |
Why?
|
| Feasibility Studies | 3 | 2021 | 589 | 0.240 |
Why?
|
| Prejudice | 2 | 2016 | 61 | 0.240 |
Why?
|
| Psychotherapy | 2 | 2017 | 102 | 0.240 |
Why?
|
| Monitoring, Ambulatory | 3 | 2015 | 56 | 0.240 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 95 | 0.230 |
Why?
|
| Goals | 1 | 2026 | 96 | 0.220 |
Why?
|
| Substance Abuse Detection | 2 | 2015 | 39 | 0.220 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2025 | 117 | 0.220 |
Why?
|
| Acute Pain | 1 | 2024 | 18 | 0.210 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 16 | 0.210 |
Why?
|
| Serotonin Antagonists | 1 | 2004 | 31 | 0.210 |
Why?
|
| Sleep Wake Disorders | 1 | 2025 | 80 | 0.210 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 159 | 0.200 |
Why?
|
| Suicide | 1 | 2026 | 143 | 0.200 |
Why?
|
| Smoking Prevention | 2 | 2015 | 163 | 0.200 |
Why?
|
| Retinal Cone Photoreceptor Cells | 4 | 1997 | 27 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 2714 | 0.190 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2002 | 8 | 0.190 |
Why?
|
| World Health Organization | 1 | 2022 | 35 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 500 | 0.180 |
Why?
|
| Epidemics | 1 | 2022 | 27 | 0.180 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2017 | 26 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2494 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2020 | 3 | 0.170 |
Why?
|
| Aged | 13 | 2026 | 15041 | 0.170 |
Why?
|
| Health Planning | 1 | 2021 | 32 | 0.170 |
Why?
|
| Social Problems | 1 | 2020 | 5 | 0.160 |
Why?
|
| Outpatients | 2 | 2012 | 143 | 0.160 |
Why?
|
| Interview, Psychological | 2 | 2017 | 78 | 0.160 |
Why?
|
| Health Personnel | 1 | 2024 | 389 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1563 | 0.160 |
Why?
|
| Public Housing | 1 | 2020 | 13 | 0.160 |
Why?
|
| Employment | 1 | 2021 | 131 | 0.160 |
Why?
|
| Patient Compliance | 3 | 2013 | 370 | 0.150 |
Why?
|
| Vaping | 1 | 2020 | 49 | 0.150 |
Why?
|
| Sex Factors | 3 | 2018 | 994 | 0.150 |
Why?
|
| Health Plan Implementation | 2 | 2017 | 40 | 0.150 |
Why?
|
| Risk Factors | 4 | 2026 | 5457 | 0.150 |
Why?
|
| Public Opinion | 1 | 2019 | 26 | 0.150 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 78 | 0.150 |
Why?
|
| Gambling | 2 | 2016 | 18 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 803 | 0.150 |
Why?
|
| Diabetes Mellitus | 3 | 2009 | 555 | 0.140 |
Why?
|
| Methadone | 4 | 2023 | 140 | 0.140 |
Why?
|
| Double-Blind Method | 5 | 2015 | 743 | 0.140 |
Why?
|
| Community Health Centers | 1 | 2019 | 98 | 0.140 |
Why?
|
| Tobacco Use | 1 | 2018 | 42 | 0.140 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 1998 | 21 | 0.140 |
Why?
|
| Recurrence | 4 | 2015 | 662 | 0.140 |
Why?
|
| Boston | 1 | 2019 | 260 | 0.140 |
Why?
|
| Program Development | 1 | 2019 | 208 | 0.130 |
Why?
|
| Color Vision Defects | 1 | 1997 | 2 | 0.130 |
Why?
|
| Psychology, Clinical | 1 | 1997 | 7 | 0.130 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 323 | 0.130 |
Why?
|
| Dopamine | 3 | 2008 | 108 | 0.130 |
Why?
|
| Los Angeles | 1 | 2017 | 14 | 0.130 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 463 | 0.130 |
Why?
|
| Needs Assessment | 2 | 2024 | 202 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 185 | 0.130 |
Why?
|
| Legislation, Medical | 1 | 2017 | 4 | 0.130 |
Why?
|
| Thinking | 1 | 2017 | 29 | 0.130 |
Why?
|
| Pandemics | 1 | 2022 | 687 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 138 | 0.130 |
Why?
|
| Logistic Models | 3 | 2020 | 1273 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2018 | 229 | 0.130 |
Why?
|
| Culture | 1 | 2017 | 82 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 201 | 0.120 |
Why?
|
| Cooperative Behavior | 2 | 2024 | 230 | 0.110 |
Why?
|
| Adolescent | 7 | 2021 | 6327 | 0.110 |
Why?
|
| Social Justice | 1 | 2016 | 33 | 0.110 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2015 | 26 | 0.110 |
Why?
|
| Memantine | 1 | 2015 | 22 | 0.110 |
Why?
|
| Naloxone | 1 | 2015 | 53 | 0.110 |
Why?
|
| Age Factors | 2 | 2018 | 1591 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 348 | 0.110 |
Why?
|
| Haloperidol | 2 | 2006 | 17 | 0.110 |
Why?
|
| Risk-Taking | 1 | 2016 | 159 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2017 | 284 | 0.110 |
Why?
|
| Bipolar Disorder | 2 | 2009 | 249 | 0.110 |
Why?
|
| Narcotic Antagonists | 1 | 2015 | 133 | 0.100 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 60 | 0.100 |
Why?
|
| Hospitalization | 2 | 2018 | 1398 | 0.100 |
Why?
|
| Reminder Systems | 1 | 2014 | 75 | 0.100 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 126 | 0.100 |
Why?
|
| Surveys and Questionnaires | 5 | 2013 | 2773 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2022 | 3320 | 0.100 |
Why?
|
| Cognition | 3 | 2023 | 508 | 0.090 |
Why?
|
| Health Behavior | 1 | 2016 | 485 | 0.090 |
Why?
|
| Clinical Competence | 1 | 1997 | 732 | 0.090 |
Why?
|
| Women's Health | 1 | 2015 | 374 | 0.090 |
Why?
|
| Child | 2 | 2020 | 4608 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 1993 | 195 | 0.090 |
Why?
|
| Research Design | 1 | 2015 | 590 | 0.090 |
Why?
|
| Training Support | 1 | 2012 | 20 | 0.090 |
Why?
|
| Motivation | 3 | 2015 | 298 | 0.090 |
Why?
|
| Skin | 1 | 2015 | 428 | 0.090 |
Why?
|
| Biomarkers | 2 | 2024 | 1474 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5646 | 0.080 |
Why?
|
| Patient Care Team | 2 | 2013 | 335 | 0.080 |
Why?
|
| Educational Status | 1 | 2012 | 279 | 0.080 |
Why?
|
| Genotype | 1 | 2012 | 674 | 0.080 |
Why?
|
| Machine Learning | 2 | 2024 | 195 | 0.080 |
Why?
|
| Psychometrics | 3 | 2005 | 394 | 0.080 |
Why?
|
| Affect | 3 | 2017 | 131 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 139 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 106 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 202 | 0.070 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 150 | 0.070 |
Why?
|
| Pharmacists | 1 | 2009 | 131 | 0.070 |
Why?
|
| Color Perception | 2 | 1997 | 4 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6934 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 2006 | 51 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 58 | 0.060 |
Why?
|
| Naltrexone | 2 | 2018 | 91 | 0.060 |
Why?
|
| New Jersey | 2 | 2004 | 24 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 3771 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2018 | 532 | 0.060 |
Why?
|
| Self Report | 2 | 2020 | 391 | 0.060 |
Why?
|
| Galvanic Skin Response | 2 | 2015 | 25 | 0.060 |
Why?
|
| Smoking | 2 | 2016 | 863 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 1709 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 461 | 0.050 |
Why?
|
| Pirenzepine | 1 | 2003 | 5 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2023 | 317 | 0.050 |
Why?
|
| HIV Infections | 1 | 2010 | 957 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 606 | 0.050 |
Why?
|
| Mental Processes | 1 | 2023 | 18 | 0.050 |
Why?
|
| England | 1 | 2022 | 28 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 1279 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2002 | 118 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2023 | 165 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 138 | 0.050 |
Why?
|
| Problem Solving | 1 | 2002 | 32 | 0.040 |
Why?
|
| Reaction Time | 1 | 2002 | 134 | 0.040 |
Why?
|
| Universities | 1 | 2022 | 168 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 372 | 0.040 |
Why?
|
| Health Promotion | 1 | 2026 | 522 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2005 | 533 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2002 | 137 | 0.040 |
Why?
|
| Dronabinol | 1 | 2020 | 31 | 0.040 |
Why?
|
| Attention | 1 | 2002 | 154 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 21 | 0.040 |
Why?
|
| Social Welfare | 1 | 2020 | 23 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 77 | 0.040 |
Why?
|
| Nicotine | 1 | 2020 | 118 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 441 | 0.040 |
Why?
|
| Chlorpromazine | 1 | 1999 | 8 | 0.040 |
Why?
|
| Mindfulness | 1 | 2020 | 72 | 0.040 |
Why?
|
| Clozapine | 1 | 1999 | 32 | 0.040 |
Why?
|
| Prevalence | 2 | 2015 | 1448 | 0.030 |
Why?
|
| Heart Rate | 1 | 2020 | 334 | 0.030 |
Why?
|
| Drive | 1 | 1997 | 2 | 0.030 |
Why?
|
| Eye Movement Measurements | 1 | 2017 | 20 | 0.030 |
Why?
|
| Communication | 1 | 2023 | 599 | 0.030 |
Why?
|
| Color Perception Tests | 1 | 1997 | 1 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2017 | 48 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2017 | 66 | 0.030 |
Why?
|
| Psychological Theory | 1 | 1997 | 26 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 887 | 0.030 |
Why?
|
| Education, Graduate | 1 | 1997 | 15 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 67 | 0.030 |
Why?
|
| Research Personnel | 1 | 1997 | 82 | 0.030 |
Why?
|
| Attitude | 1 | 2017 | 100 | 0.030 |
Why?
|
| Eye Movements | 1 | 2017 | 86 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 230 | 0.030 |
Why?
|
| Retina | 1 | 1997 | 135 | 0.030 |
Why?
|
| Teaching | 1 | 1997 | 165 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 518 | 0.030 |
Why?
|
| Skin Temperature | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2002 | 2631 | 0.030 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2010 | 104 | 0.030 |
Why?
|
| Motion | 1 | 2015 | 65 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 160 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 742 | 0.030 |
Why?
|
| Body Temperature | 1 | 2015 | 46 | 0.030 |
Why?
|
| Wrist | 1 | 2015 | 39 | 0.030 |
Why?
|
| Motor Activity | 1 | 2017 | 346 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 468 | 0.030 |
Why?
|
| Medicare | 2 | 2009 | 627 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 857 | 0.020 |
Why?
|
| Primary Prevention | 1 | 1993 | 137 | 0.020 |
Why?
|
| Health Education | 1 | 1993 | 190 | 0.020 |
Why?
|
| Wireless Technology | 1 | 2012 | 14 | 0.020 |
Why?
|
| Vocational Guidance | 1 | 2012 | 19 | 0.020 |
Why?
|
| Mass Screening | 1 | 1996 | 700 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 265 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 327 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 94 | 0.020 |
Why?
|
| Drug Packaging | 1 | 2009 | 11 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 178 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 1272 | 0.020 |
Why?
|
| Population | 1 | 2007 | 14 | 0.020 |
Why?
|
| Classification | 1 | 2007 | 13 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2005 | 56 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2005 | 147 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 125 | 0.010 |
Why?
|
| Benztropine | 1 | 2003 | 2 | 0.010 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2003 | 5 | 0.010 |
Why?
|
| Muscarinic Antagonists | 1 | 2003 | 34 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 80 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 220 | 0.010 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1999 | 1 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1999 | 6 | 0.010 |
Why?
|
| Color | 1 | 1997 | 26 | 0.010 |
Why?
|
| Weight Gain | 1 | 1999 | 165 | 0.010 |
Why?
|
| Arousal | 1 | 1996 | 42 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 328 | 0.010 |
Why?
|
| Patient Admission | 1 | 1996 | 198 | 0.010 |
Why?
|
| Incidence | 1 | 1996 | 1427 | 0.010 |
Why?
|